Aicore Life Sciences Netherlands

Corporate Social Responsibility

Mauris amet donec nisl sed nec. Aliquam metus nunc lorem fusce. Egestas senectus tincidunt ornare nibh fames odio.

Mauris amet donec nisl sed nec. Aliquam metus nunc lorem fusce. Egestas senectus tincidunt ornare nibh fames odio.

Mauris amet donec nisl sed nec. Aliquam metus nunc lorem fusce. Egestas senectus tincidunt ornare nibh fames odio.

Mauris amet donec nisl sed nec. Aliquam metus nunc lorem fusce. Egestas senectus tincidunt ornare nibh fames odio.

About The Company

With having a collective background of employment by Organon, we share its same refreshing values, corporate culture and vision. In 2018 we decided to join efforts to revive the standards and reputation of one of the world’s market leaders in women’s health.

Each of us contributes in a uniquely different way to Aicore Life Sciences:

  • excellence in clinical trials;
  • years of management and consultancy in a vast range of life science businesses;
  • owned distribution and marketing facilities.

 

And all this with the energy and enthusiasm intrinsic to enterprises making their way in a highly competitive environment.

Aicore Life Sciences, inheriting the vision of Organon, pursues the goal of developing an upgraded portfolio of gynecological products. The emphasis is on cutting-edge generics as well as on original products targeting market niches with moderate competition.

Moreover, the company is ready to embody its innovative spirit in designing know-how “beyond the molecule”: better ways of applying medicine, alternative drug dosage forms and other ways of making the use of drugs more convenient and effective. This singles out the product on the shelf and enhances women’s quality of life.

The merge of different competences and innovative zeal feeds our ambition to grow into a distinguished player in its segment within the next five years.

Associated companies

We are a relatively young company, but have the benefit of standing on the shoulders of a number of experienced market players, giving us competencies unusual for, and far beyond ordinary start-ups:

  • access to all R&D facilities required for drug development;
  • marketing and sales;
  • deep knowledge of life sciences;
  • rapidly expanding distribution network across Europe.

CLS-Ukraine is a combined contract research – and site management organization (CRO/SMO) with a strong commitment to excellence in performing clinical trials and meeting customer needs. Staffed with seven experts, for five years CLS-Ukraine has had the pleasure of cooperating with a number of high-level scientific institutions and well-established players in the pharmaceutical market. Among them are Ghent University, Merck, Ferring, Orion, Besins and Columbia laboratories. CLS-Ukraine runs clinical trials in a number of East European countries.

Eagle Rock Life Sciences is an independent international life sciences consultancy, offering a broad range of services, including R&D, Regulatory, IP & Legal, Strategy and Business Development, Finance, M&S. A cross-functional team of more than 30 associates meet the issues of the most demanding clients from the pharmaceutical market, such as Sanofi, Gedeon Richter, Dinox, Sanquin and others. We provide support to life sciences enterprises from early start-ups to mature companies and view ourselves as hands-on specialists.

Aicore is a European pharmaceutical company active in the development, manufacture and distribution of medications, whose efficacy has been established with evidence-based practice. With eight products to offer, the company operates in seven European countries, expanding its portfolio and geography every year.

Board

Career milestones:

  • Since 1982 in pharma;
  • Worked for AKZO Pharma, The Netherlands, in period 1982-1988 as corporate strategic planner (Organon) and product manager Biochemical Products (Diosynth);
  • Today is an Associate Partner in Eagle Rock Life Sciences, The Netherlands, responsible for mergers & acquisitions and new business development.
  • Daily Management of the Company Strategy & Development, Production & Quality Assurance, IP & Legal since 2018.

 

Key competences:

  • Dr. Peter Ruifrok is a highly qualified and seasoned CEO with extensive Dutch and European experience. He worked for many different companies, ranging from major multinational PLC’s to SME’s, from existing businesses to start-ups. For eight years he had his own company in the UK.
  • He specializes in M&As and hence financing, integrations, turnarounds, reorganizations, investments and due diligences, with similar skills in new business development. He is a pur sang entrepreneur with the accompanying vision and leadership qualities.
  • He is hands-on, has excellent conceptual, communication and commercial skills (customer focus), brings structure, and is a team builder, result oriented with a good feeling for both man and process.
  • Peter Ruifrok studied chemistry and pharmacy at the Groningen University in The Netherlands, where he also obtained his PhD.

Dr. Peter G. Ruifrok

Chief Executive Officer

Career milestones:

  • Since 1994 in Health Care, MD, worked as a Surgeon;
  • Since 2000 in pharma on different position in sales and marketing;
  • Worked for Organon as Sales Manager in Ukraine;
  • Assistant professor, Cathedra of Surgery, University Shevchenko since 2021;
  • Global Marketing Head since 2018.

 

Key competences:

  • Launch and development of marketing and distribution organizations in Ukraine, Romania, Bulgaria, Serbia, Croatia, Poland, Moldova during last decades.
  • Creating of portfolio of own products under Aicore’s trademark.
  • Experienced in marketing, sales and product development in different areas: products for women’s health, intensive care, cardiology, over-the-counter medications.

Dr. Andrey Lovin

Chief Operating Officer

Search for new products and partners. Managing marketing, sales and distribution of Aicore Life Sciences products in Europe and worldwide via own organisations and exclusive distribution agreements.

Career milestones:

  • Medical Doctor by background, PhD and MBA;
  • Since 1994 in pharma;
    Directed Ukrainian subsidiaries of Hemofarm (FRY), Bionorica (Germany);
  • Joined Organon in 2002 and managed Organon Ukraine (as GM) until it was acquired by Schering Plough in 2008;
  • From late 2008 he has worked in independent international consulting and project management for pharmaceutical companies in the field of R&D, clinical development, and market access. Managed big R&D projects in Ukraine and CIS for Columbia Laboratories, Besins, Merck;
  • In 2014 co-founded CLS-Ukraine, a regional CRO/SMO. Today he continues managing complex projects in the field of R&D (formulation development, pre-clinical, Phase 1-3) and market entry.
  • Management of R&D activities, Regulatory, Medical and Scientific Affairs, Portfolio strategy since 2018.

 

Key competences:

  • Since 1994 Dr. Roman Byshovets has experience in pharmaceutical and medical business with a wide range of indication areas in Ukrainian and CIS assignments.
  • He enjoys an unique combination of competences, based on his work as GM, of sales and marketing organizations; deep involvement into the management of R&D projects; medical background by education expanded by the job skills training.
  • Deep understanding of market drivers and personal involvement into development and implementation of local Company strategies; business and marketing plans resulting in successful growth and excellent market results of companies which he managed.
  • Management of R&D projects organically added competencies that provide a strategic vision of the entire cycle of a medicine from a test tube in a scientific laboratory to the pharmacy shelf.
  • Roman Byshovets studied medicine at the National Medical University in Kyiv, Ukraine, where he also did his MD and PhD and received his MBA from the International Management Institute in Kyiv.

Dr. Roman V. Byshovets

Director of Research & Development, Medical and Scientific Affairs